Biotech Values

[DewDiligence]

New Survey on Roche Acquisition of Genentech

Roche has offered $89/sh in cash for the 44% of DNA’s shares it does not already own. Now Roche must negotiate a deal with DNA’s BoD and also obtain approval of the deal by a majority of DNA’s non-Roche shareholders.

The buyout price in the final deal will be:

a) $89-94
b) $95-104
c) $105-114
d) $115-124
e) $125 or more
f) None—the deal will not go through

To vote, go to
http://www.investorshub.com/boards/board_surveymenu.asp?board_id=1418
and select survey #104.